American Heart Association

A clinical trial found exenatide, a GLP-1 analog, did not reduce death, stroke, or organ failure risks during heart surgeries with bypass. The GLORIOUS trial, involving 1,400 adults in Denmark, showed no significant differences in outcomes between exenatide and placebo groups over a 6-year follow-up.

Plozasiran demonstrated deep and sustained triglyceride reductions, impacting lipoproteins linked to atherosclerotic cardiovascular disease, with similar responses in genetically confirmed and clinically diagnosed FCS patients. Mean reductions reached -73% in MUIR and -86% in SHASTA-2, with favorable reductions in remnant cholesterol and non-HDL-cholesterol over 15 months.

Syndax Pharmaceuticals wins FDA approval for Revuforj, a leukemia treatment; Cybin's psilocin-based drug shows efficacy in treating depression; Neurogene halts high-dose gene therapy for Rett syndrome due to safety concerns; Eli Lilly's Zepbound reduces heart failure-related hospitalizations in trial.

Arrowhead Pharmaceuticals submitted a New Drug Application to the FDA for plozasiran to treat familial chylomicronemia syndrome, a disease with no current FDA-approved treatments. The submission is supported by positive results from the Phase 3 PALISADE study, which demonstrated significant reductions in triglycerides and acute pancreatitis risk.

LIBERATE-OLE trial results presented at AHA 2024 show lerodalcibep, a long-acting PCSK9 inhibitor, significantly reduces LDL-C in HeFH patients, with 80% achieving >50% LDL-C reduction and 70% reaching recommended targets over 72 weeks. Lerodalcibep is well-tolerated and offers a once-monthly injection convenience, potentially improving adherence.

The Global Anisindione Market is projected to grow from US$ 185.8 million in 2023 to US$ 329.6 million by 2033, driven by the rising incidence of thromboembolic disorders and the need for effective anticoagulant therapies. Anisindione, a synthetic anticoagulant, is used for treating venous thrombosis and pulmonary embolism. The market faces competition from newer anticoagulants but holds potential in emerging markets and personalized medicine approaches.

Intellia Therapeutics announced positive Phase 1 trial data for nex-z in ATTR amyloidosis, showing rapid, deep, and durable serum TTR reduction, disease stabilization or improvement, and favorable safety profile. Data presented at the 2024 AHA Scientific Sessions and published in the New England Journal of Medicine.

Nucresiran, an RNAi therapeutic for ATTR amyloidosis, showed rapid TTR knockdown of >90% by Day 15 and >96% by Day 29, with potential for biannual or annual dosing. The drug was well-tolerated, with plans for Phase 3 development in Q1 2025.

A study in seven low- and middle-income countries found reconditioned pacemakers to be as safe and effective as new ones at 90 days post-implantation, potentially offering affordable options for patients. The 'My Heart Your Heart' study, presented at the American Heart Association's Scientific Sessions 2024, compared the function and safety of reconditioned pacemakers to new devices in nearly 300 adults. While the study suggests positive outcomes, longer-term research is needed to confirm the devices' long-term safety and effectiveness.

RN0191, a PCSK9 siRNA, showed up to 95% individual and 87% mean maximum PCSK9 reduction, and up to 74% individual and 56% mean maximal LDL-C lowering in a Phase 1 trial. The robust and sustainable effects support bi-annual dosing, with potential as a best-in-class therapy for reducing atherosclerosis cardiovascular risk.